DG

Deep Genomics Company Research Report



Company Overview


  • Name: Deep Genomics


  • Mission: The mission of Deep Genomics is to leverage revolutions in AI, RNA biology, and automation to enable a new approach to drug development. They aim to program RNA therapies for any gene and any genetic condition, positioning themselves at the forefront of AI-powered drug discovery.


  • Founding Year and Founders: Deep Genomics was founded in 2015 by Brendan Frey, Ph.D.


  • Key People:

  • Brian O'Callaghan, M.B.A. – Chief Executive Officer

  • Brendan Frey, Ph.D. – Chief Innovation Officer and Founder

  • David Johnston, M.B.A. – Chief Financial Officer

  • Matt Cahill, J.D., M.B.A., Ph.D. – Chief Strategy Officer

  • Clive Bertram – Chief Business Officer

  • Tom Masterson, M.B.A. – Chief Operating Officer

  • Greg Hoffman, Ph.D. – Chief Scientific Officer

  • Radu Dobrin – Chief Technology Officer

  • Jing Ge, Ph.D. – Vice President of Strategy and Business Development

  • Troy Simpson – Vice President and Head of Research Operations

  • Asha Rostamianfar, M.Sc. – Vice President and Head of Engineering

  • Tehmina Masud, Ph.D., MBSS – Vice President and Head of Target Identification

  • Joel Shor – Vice President and Head of Machine Learning


  • Headquarters: 480 University Avenue, Suite 1300, Toronto, Ontario, Canada, M5G 1V2


  • Number of Employees: Over 100 team members


  • Revenue: No information is available


  • Known For: Deep Genomics is known for its AI-powered platform which mines RNA biology data to develop therapies for genetic conditions. They are renowned for their flagship platform, BigRNA, which is the world’s first RNA foundation model for RNA therapeutics.


Products



BigRNA


  • Description: BigRNA is a proprietary AI platform designed for data-driven prediction, identifying novel genetic targets, and evaluating therapeutic candidates.

  • Key Features:

  • Ability to predict RNA expression at sub-gene resolution.

  • Excellent at identifying targets and discovering novel biological mechanisms.

  • Predicts molecule-target interactions.

  • Designs RNA therapeutic candidates across various RNA therapeutic modalities including oligonucleotides, DNA editing, RNA editing, and mRNA.


Recent Developments



  • New CEO Appointment: In September 2023, Brian O'Callaghan was appointed as the CEO as part of a plan to evolve Deep Genomics into a forward-integrated biopharmaceutical company. The founder, Brendan Frey, transitioned to the role of Chief Innovation Officer.


  • Expansion of Leadership and Operations: In June 2024, Deep Genomics celebrated the opening of a new office and lab facility in Cambridge, Massachusetts. This expansion is part of their strategic growth initiative.


  • Partnerships:

  • In September 2021, Deep Genomics announced a collaboration with Mila, the Quebec Artificial Intelligence Institute, allowing them to take advantage of Mila's AI advancements.


  • Notable AI Advancements:

  • In September 2023, Deep Genomics introduced BigRNA, the first transformer neural network for the discovery of RNA biology and therapeutics.

  • The development of BigRNA+ to expand the number of mechanisms and genetic variants for tackling more complex genetic diseases.


  • Presentations and Recognition:

  • Deep Genomics presented at the 2023 Elevate Festival and the 40th Annual J.P. Morgan Healthcare Conference.

  • The company regularly publishes significant contributions in peer-reviewed journals.


Publications


  • "An RNA foundation model enables discovery of disease mechanisms and candidate therapeutics" – Celaj et al., BioRxiv, September 2023.

  • "A curated census of pathogenic and likely pathogenic UTR variants and evaluation of deep learning models for variant effect prediction" – Bohn et al., Front. Mol. Biosci., September 2023.

  • "Transcriptome-wide off-target effects of steric-blocking oligonucleotides" – Holgersen et al., Nucleic Acid Ther., December 2021.


Contact Information


  • Address: 480 University Avenue, Suite 1300, Toronto, Ontario, Canada, M5G 1V2

  • Press Enquiries: press@deepgenomics.com





© 2024 DEEP GENOMICS. ALL RIGHTS RESERVED. PRIVACY POLICY